Journals / Sakarya Tıp Dergisi / 2013 / Cilt: 3 - Sayı: 3

Evaluation of clinical properties of dexmedetomidine in terms of procedural sedation and analgesia

Prosedüral sedasyon ve analjezi açısından dexmedetomidinin klinik özelliklerinin değerlendirilmesi

Pages
115–121
Publication Date
2013-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we efforted to demonstrate that clinical properties of dexmedetomidine an alpha-2 agonist agent which- is used for procedural sedation and analgesia in the light of current literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sedation for the short-term but potentially painful procedures is of often used in emergency service.
📊
Key Findings & Data:Objective in sedation is to ensure the conditions in which the patient can conveniently tolerate the process throughout the process.
💡
Conclusion & Impact:In this study, we efforted to demonstrate that clinical properties of dexmedetomidine an alpha-2 agonist agent which- is used for procedural sedation and analgesia in the light of current literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:deksmedetomidin · klinik özellikler · prosedüral sedasyon

Abstract

Sedation for the short-term but potentially painful procedures is of often used in emergency service. In addition to its ability to provide an ideal sedative regime analgesia and anxiolytics, it must create minimal side effects, protect arterial reflexes, must not cause cardiorespiratory depression and must allow rapid recovery subsequent to the procedure. Objective in sedation is to ensure the conditions in which the patient can conveniently tolerate the process throughout the process. In this study, we efforted to demonstrate that clinical properties of dexmedetomidine an alpha-2 agonist agent which- is used for procedural sedation and analgesia in the light of current literature.

Özet

Kısa süreli fakat potansiyel olarak ağrılı prosedürler için sedasyon, sıklıkla acil serviste uygulanmaktadır. İdeal bir sedatif rejimi analjezi ve anksiyoliz sağlaması yanısıra minimal yan etki oluşturmalı, havayolu reflekslerini korumalı, kardiyorespiratuvar depresyona yol açmamalı ve prosedür sonrası hızlı derlenmeye olanak vermelidir. Sedasyondaki amaç, hastanın işlem boyunca işlemi rahat tolere edebileceği şartları sağlamaktır.Biz bu çalışmada, prosedüral sedasyon ve analjezi için kullanılan bir alfa-2 agonist ajan olan dexmedetomidinin klinik özelliklerini güncel literatür ışığında açıklamaya çalıştık.

🔖

Cite This Article

Kaya, R., Dokur, M. (2013). Evaluation of clinical properties of dexmedetomidine in terms of procedural sedation and analgesia. Sakarya Tıp Dergisi, Cilt: 3 - Sayı: 3, 115–121. https://ajindex.com/articles/261764

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Scheinin B, Lindgren L, Randell T, Scheinin H, Scheinin M. Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and perioperative fentanyl. Br J Anaesth 1992;68:126–131.
  2. Hoy SM, Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71(11):1481- 1501. Symington L, Thakore S. A review of the use of propofol for procedural sedation in the emergency department. Emerg Med J. 2006;23(2):89-93.
  3. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30(12):2188-2196.
  4. Avitsian R, Lin J, Lotto M, Ebrahim Z. Dexmedetomidine and awake fiberoptic intubation for possible cervical spine myelopathy: a clinical series. J Neurosurg Anesthesiol. 2005;17(2):97-99.
  5. Bergese SD, Khabiri B, Roberts WD, Howie MB, McSweeney TD, Gerhardt MA. Dexmedetomidine for conscious sedation in difficult awake fiberoptic intubation cases. J Clin Anesth. 2007;19(2):141-144. Multz AS. Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg. 2003;96(4):1054-1055.
  6. Shukry M, Clyde MC, Kalarickal PL, Ramadhyani U.Does dexmedetomidine prevent emergence delirium in children after sevoflurane-based general anesthesia? Paediatr Anaesth. 2005;15(12):1098-1104.
  7. Leroy PL, Gorzeman MP, Sury MR. Procedural sedation and analgesia in children by non-anesthesiologists in an emergency department. Minerva Pediatr. 2009;61:193-215.
  8. Chrysostomou C, Schmitt CG. Dexmedetomidine: sedation, analgesia and beyond. Expert Opin Drug Metab Toxicol. 2008;4(5):619-627.
  9. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489-499.
  10. Mato M, Pérez A, Otero J, Torres LM. Dexmedetomidine, a promising drug. Rev Esp Anestesiol Reanim. 2002;49(8):407-420.
  11. Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90(3):699-705.
  12. Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive car